Data that consumers directly collect about their health or cardiovascular disease management through digital health technologies may explain, influence and/or predict health-related outcomes. Digital biomarkers may aid in the management of chronic cardiovascular diseases, but many gaps remain that have impeded the realization of the full potential of digital biomarkers. This panel discussion will cover these gaps and propose solutions that will likely transform healthcare delivery and achievement of better outcomes with special emphasis on arrhythmias, heart failure, hypertension, and diabetes.
Co-Founder and CEO | Professor of Medicine
VPG Medical Inc. | University of Rochester Medical School
Chief Commercial Officer | Board Director | Faculty Lecturer and Practicing Physician | Author | Entrepreneur
Everly Health | Harvard Medical School
Digital Biomarkers and Therapeutics – How will they look in 2025 and 2030?
September 21, 2023 | 03:30 PM (PST) - 04:30 PM (PST)